SG10201912109QA - Salt form of a human hi stone methyltransf erase ezh2 inhibitor - Google Patents
Salt form of a human hi stone methyltransf erase ezh2 inhibitorInfo
- Publication number
- SG10201912109QA SG10201912109QA SG10201912109QA SG10201912109QA SG10201912109QA SG 10201912109Q A SG10201912109Q A SG 10201912109QA SG 10201912109Q A SG10201912109Q A SG 10201912109QA SG 10201912109Q A SG10201912109Q A SG 10201912109QA SG 10201912109Q A SG10201912109Q A SG 10201912109QA
- Authority
- SG
- Singapore
- Prior art keywords
- stone
- human
- salt form
- ezh2 inhibitor
- methyltransf erase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261624215P | 2012-04-13 | 2012-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912109QA true SG10201912109QA (en) | 2020-02-27 |
Family
ID=49328166
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
SG10201912109QA SG10201912109QA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406468YA SG11201406468YA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
SG10201608577RA SG10201608577RA (en) | 2012-04-13 | 2013-04-11 | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
Country Status (25)
Country | Link |
---|---|
US (6) | US9394283B2 (en) |
EP (4) | EP3628670B1 (en) |
JP (3) | JP6255382B2 (en) |
KR (3) | KR102120883B1 (en) |
CN (2) | CN104603130B (en) |
AU (2) | AU2013245878B2 (en) |
BR (1) | BR112014025508B1 (en) |
CA (1) | CA2870005C (en) |
CY (2) | CY1119383T1 (en) |
DK (3) | DK2836491T3 (en) |
ES (3) | ES2931316T3 (en) |
HR (2) | HRP20170295T1 (en) |
HU (3) | HUE031976T2 (en) |
IL (4) | IL282732B2 (en) |
IN (1) | IN2014DN09068A (en) |
LT (2) | LT2836491T (en) |
MX (1) | MX362339B (en) |
NZ (1) | NZ700761A (en) |
PL (3) | PL3628670T3 (en) |
PT (3) | PT2836491T (en) |
RS (2) | RS55690B1 (en) |
RU (1) | RU2658911C2 (en) |
SG (3) | SG11201406468YA (en) |
SI (2) | SI3184523T1 (en) |
WO (1) | WO2013155317A1 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
KR20230004871A (en) | 2012-04-13 | 2023-01-06 | 에피자임, 인코포레이티드 | Combination therapy for treating cancer |
SG11201406468YA (en) * | 2012-04-13 | 2015-01-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
PE20150887A1 (en) | 2012-10-15 | 2015-06-04 | Epizyme Inc | SUBSTITUTE BENZENE COMPOUNDS |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2991980B1 (en) | 2013-04-30 | 2019-01-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | Enhancer of zeste homolog 2 inhibitors |
US9556157B2 (en) | 2013-07-10 | 2017-01-31 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
JP2016533364A (en) * | 2013-10-18 | 2016-10-27 | エピザイム,インコーポレイティド | How to treat cancer |
US9738630B2 (en) | 2013-11-19 | 2017-08-22 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
ES2863996T3 (en) | 2013-12-06 | 2021-10-13 | Epizyme Inc | Combination therapy for cancer treatment |
CN106999498B (en) | 2014-06-17 | 2021-06-08 | Epizyme股份有限公司 | EZH2 inhibitors for the treatment of lymphoma |
ES2725928T3 (en) | 2014-06-20 | 2019-09-30 | Constellation Pharmaceuticals Inc | Crystal forms of 2 - ((4S) -6- (4-chlorophenyl) -1-methyl-4H-benzo [c] isoxazolo [4,5-e] azepin-4-yl) acetamide |
MX2017004969A (en) | 2014-10-16 | 2017-07-19 | Epizyme Inc | Method for treating cancer. |
BR112017010166A2 (en) * | 2014-11-17 | 2018-02-14 | Eisai R&D Man Co Ltd | solid tumor treatment method, activity inhibition method, oral dosage form for treating a solid tumor, solid pharmaceutical formulation, process for preparing a pharmaceutical formulation, and solid pharmaceutical composition |
TW201636344A (en) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Inhibitors of EZH2 |
EP3285773A4 (en) | 2015-04-20 | 2019-04-10 | Epizyme, Inc. | Combination therapy for treating cancer |
EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
CA3011186A1 (en) | 2016-01-29 | 2017-08-03 | Epizyme, Inc. | Combination therapy for treating cancer |
CA3025933A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
MA45406A (en) | 2016-06-17 | 2019-04-24 | Epizyme Inc | EZH2 INHIBITORS TO TREAT CANCER |
EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
WO2018137639A1 (en) * | 2017-01-25 | 2018-08-02 | 恩瑞生物医药科技(上海)有限公司 | Histone methyltransferase ezh2 inhibitor, preparation method and pharmaceutical use thereof |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
JP7399079B2 (en) | 2017-09-05 | 2023-12-15 | エピザイム,インコーポレイティド | Combination therapy to treat cancer |
JP2021531340A (en) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | Inhibition of the PRC2 subunit to treat eye disorders |
WO2021035194A1 (en) | 2019-08-22 | 2021-02-25 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
EP4077314A1 (en) * | 2019-12-20 | 2022-10-26 | Epizyme, Inc. | Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer |
WO2022208552A1 (en) * | 2021-03-31 | 2022-10-06 | Msn Laboratories Private Limited, R&D Center | Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733729A (en) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Production of n-cyano-n'-substituted-arylcarboxyimidamide compound |
AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
DE19516776A1 (en) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin regulatory genes |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
AU6060099A (en) | 1998-09-30 | 2000-04-17 | Procter & Gamble Company, The | 2-substituted ketoamides |
UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
ATE438624T1 (en) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-PYRIDONE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID TYPE 2 RECEPTOR |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
BRPI0508230A (en) * | 2004-03-30 | 2007-07-17 | Chiron Corp | substituted thiophene derivatives as anti-cancer agents |
JP5160885B2 (en) | 2004-06-01 | 2013-03-13 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Reconstituted histone methyltransferase complex and method for identifying modulators thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
EP1891434B1 (en) | 2005-06-02 | 2011-01-05 | The University of North Carolina at Chapel Hill | Purification, characterization and reconstitution of a ubiquitin e3 ligase |
FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
WO2007050347A1 (en) | 2005-10-21 | 2007-05-03 | Merck & Co., Inc. | Potassium channel inhibitors |
CA2622615A1 (en) | 2005-10-28 | 2007-05-10 | The University Of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
US8163749B2 (en) | 2005-12-14 | 2012-04-24 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
RU2008149246A (en) | 2006-05-15 | 2010-06-20 | Айрм Ллк (Bm) | TERPHTHALATE BASED COMPOUND, COMPOSITIONS AND THEIR APPLICATION AS HIV INTEGRAS INHIBITORS |
US20070287706A1 (en) | 2006-05-18 | 2007-12-13 | Dickson John K Jr | Certain substituted quinolones, compositions, and uses thereof |
EP2086318A4 (en) | 2006-10-10 | 2009-12-23 | Burnham Inst Medical Research | Neuroprotective compositions and methods |
WO2008103277A2 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
DE102007017884A1 (en) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
DE102007047737A1 (en) * | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidine and piperazine derivatives |
AU2008319308B2 (en) | 2007-10-31 | 2013-01-31 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
JP5511680B2 (en) | 2007-12-19 | 2014-06-04 | キャンサー・リサーチ・テクノロジー・リミテッド | Pyrido [2,3-B] pyrazine-8-substituted compounds and uses thereof |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
EP2323660A2 (en) | 2008-08-08 | 2011-05-25 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
FR2934995B1 (en) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
BR112012028556A2 (en) * | 2010-05-07 | 2014-04-01 | Glaxosmithkline Llc | INDOS |
WO2012005805A1 (en) | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
US8846935B2 (en) * | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
RU2618475C2 (en) | 2010-09-10 | 2017-05-03 | Эпизайм, Инк. | Human ezh2 inhibitors and methods of application thereof |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
JP5908493B2 (en) | 2010-12-01 | 2016-04-26 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Indole |
RU2013130253A (en) | 2010-12-03 | 2015-01-10 | Эпизайм, Инк. | 7-DEAZAPURINE HISTONIC METHYL TRANSFERASES AND WAYS OF THEIR APPLICATION |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (en) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
TWI598336B (en) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | Substituted benzene compounds |
ES2718900T3 (en) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Human EZH2 inhibitors and methods of use thereof |
SG11201406468YA (en) | 2012-04-13 | 2015-01-29 | Epizyme Inc | Salt form of a human hi stone methyltransf erase ezh2 inhibitor |
KR20230004871A (en) | 2012-04-13 | 2023-01-06 | 에피자임, 인코포레이티드 | Combination therapy for treating cancer |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
AU2014337300B2 (en) | 2013-10-16 | 2019-01-03 | Eisai R&D Management Co., Ltd. | Hydrochloride salt form for EZH2 inhibition |
-
2013
- 2013-04-11 SG SG11201406468YA patent/SG11201406468YA/en unknown
- 2013-04-11 PL PL19180479.8T patent/PL3628670T3/en unknown
- 2013-04-11 SG SG10201608577RA patent/SG10201608577RA/en unknown
- 2013-04-11 RU RU2014145544A patent/RU2658911C2/en not_active Application Discontinuation
- 2013-04-11 PL PL16191716T patent/PL3184523T3/en unknown
- 2013-04-11 ES ES19180479T patent/ES2931316T3/en active Active
- 2013-04-11 MX MX2014012380A patent/MX362339B/en active IP Right Grant
- 2013-04-11 EP EP19180479.8A patent/EP3628670B1/en active Active
- 2013-04-11 SI SI201331566T patent/SI3184523T1/en unknown
- 2013-04-11 IL IL282732A patent/IL282732B2/en unknown
- 2013-04-11 DK DK13774979.2T patent/DK2836491T3/en active
- 2013-04-11 HU HUE13774979A patent/HUE031976T2/en unknown
- 2013-04-11 EP EP13774979.2A patent/EP2836491B1/en active Active
- 2013-04-11 HU HUE19180479A patent/HUE060881T2/en unknown
- 2013-04-11 PL PL13774979T patent/PL2836491T3/en unknown
- 2013-04-11 AU AU2013245878A patent/AU2013245878B2/en active Active
- 2013-04-11 EP EP22200677.7A patent/EP4190777A1/en active Pending
- 2013-04-11 WO PCT/US2013/036193 patent/WO2013155317A1/en active Application Filing
- 2013-04-11 KR KR1020147030684A patent/KR102120883B1/en active IP Right Grant
- 2013-04-11 KR KR1020207015664A patent/KR102438340B1/en active IP Right Grant
- 2013-04-11 LT LTEP13774979.2T patent/LT2836491T/en unknown
- 2013-04-11 SI SI201330551A patent/SI2836491T1/en unknown
- 2013-04-11 RS RS20170198A patent/RS55690B1/en unknown
- 2013-04-11 KR KR1020227029511A patent/KR20220123339A/en not_active Application Discontinuation
- 2013-04-11 SG SG10201912109QA patent/SG10201912109QA/en unknown
- 2013-04-11 CN CN201380030902.3A patent/CN104603130B/en active Active
- 2013-04-11 IN IN9068DEN2014 patent/IN2014DN09068A/en unknown
- 2013-04-11 HU HUE16191716A patent/HUE045353T2/en unknown
- 2013-04-11 PT PT137749792T patent/PT2836491T/en unknown
- 2013-04-11 LT LTEP16191716.6T patent/LT3184523T/en unknown
- 2013-04-11 US US14/394,431 patent/US9394283B2/en active Active
- 2013-04-11 BR BR112014025508-3A patent/BR112014025508B1/en active IP Right Grant
- 2013-04-11 CN CN201810245662.3A patent/CN108358899B/en active Active
- 2013-04-11 DK DK16191716.6T patent/DK3184523T3/en active
- 2013-04-11 PT PT16191716T patent/PT3184523T/en unknown
- 2013-04-11 NZ NZ700761A patent/NZ700761A/en unknown
- 2013-04-11 PT PT191804798T patent/PT3628670T/en unknown
- 2013-04-11 CA CA2870005A patent/CA2870005C/en active Active
- 2013-04-11 IL IL296199A patent/IL296199A/en unknown
- 2013-04-11 ES ES13774979.2T patent/ES2617379T3/en active Active
- 2013-04-11 JP JP2015505912A patent/JP6255382B2/en active Active
- 2013-04-11 RS RSP20191175 patent/RS59392B1/en unknown
- 2013-04-11 ES ES16191716T patent/ES2745016T3/en active Active
- 2013-04-11 EP EP16191716.6A patent/EP3184523B1/en active Active
- 2013-04-11 DK DK19180479.8T patent/DK3628670T3/en active
-
2014
- 2014-10-07 IL IL235045A patent/IL235045B/en active IP Right Grant
-
2016
- 2016-06-30 US US15/199,522 patent/US9872862B2/en active Active
-
2017
- 2017-02-22 HR HRP20170295TT patent/HRP20170295T1/en unknown
- 2017-03-06 CY CY20171100290T patent/CY1119383T1/en unknown
- 2017-10-12 JP JP2017198642A patent/JP6634058B2/en active Active
- 2017-12-11 US US15/837,390 patent/US10245269B2/en active Active
-
2018
- 2018-01-09 AU AU2018200168A patent/AU2018200168B2/en active Active
- 2018-10-02 JP JP2018187463A patent/JP2018199740A/en active Pending
-
2019
- 2019-02-08 US US16/270,752 patent/US10821113B2/en active Active
- 2019-04-21 IL IL266165A patent/IL266165B/en active IP Right Grant
- 2019-09-13 HR HRP20191653TT patent/HRP20191653T1/en unknown
- 2019-09-18 CY CY20191100981T patent/CY1122883T1/en unknown
-
2020
- 2020-09-25 US US17/032,432 patent/US11491163B2/en active Active
-
2022
- 2022-09-29 US US17/936,555 patent/US20230140327A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282732A (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor | |
IL259958B (en) | Heterocyclic inhibitors of glutaminase | |
IL232599A (en) | Hydrobromide salt of pridopidine | |
EP2903613A4 (en) | Inhibitors of irak4 activity | |
EP2903617A4 (en) | Inhibitors of irak4 activity | |
EP2678018A4 (en) | Combination of kanase inhibitors and uses thereof | |
IL270748B (en) | Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors | |
EP2760853A4 (en) | Novel salts of alogliptin | |
ZA201401417B (en) | Novel soft rock inhibitors | |
PL2709584T3 (en) | Sensory use of 6-cyclopentylidenehexane derivatives | |
ZA201205358B (en) | Use of a salt of bistetrazolylamine | |
ZA201308872B (en) | Use of a dinitromethane salt |